Children's Oncology Group's 2013 blueprint for research: Neuroblastoma

Chronic Health Conditions in Adult Survivors of Childhood Cancer

Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N., Hobbie, W., Kadan-Lottick, N. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmsa060185 · Cited by 3,597

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294

Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage

Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262

Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas

Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010

Recent Advances in Neuroblastoma

Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

Cohn, S. L., Pearson, A. D. J., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Faldum, A., Hero, B., Iehara, T., Machin, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6785 · Cited by 1,910

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835

Identification of ALK as a major familial neuroblastoma predisposition gene

Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407

Epigenetic protein families: a new frontier for drug discovery

Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327

The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report

Monclair, T., Brodeur, G. M., Ambros, P. F., Brisse, H. J., Cecchetto, G., Holmes, K., Kaneko, M., London, W. B., Matthay, K. K., Nuchtern, J. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6876 · Cited by 1,150

Targeting MYC dependence in cancer by inhibiting BET bromodomains

Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., & Sims, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108190108 · Cited by 1,110

The International Neuroblastoma Pathology Classification (the Shimada system)

Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J.-I., Joshi, V. V., Roald, B., Stram, D. O., Gerbing, R. B., Lukens, J. N., Matthay, K. K., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990715)86:2<364::aid-cncr21>3.0.co;2-7 · Cited by 1,067

Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

Molenaar, J. J., Koster, J., Zwijnenburg, D. A., van Sluis, P., Valentijn, L. J., van der Ploeg, I., Hamdi, M., van Nes, J., Westerman, B. A., van Arkel, J., et al. (2012) · Nature · doi:10.1038/nature10910 · Cited by 870

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858

Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.

Look, A. T., Hayes, F. A., Shuster, J. J., Douglass, E. C., Castleberry, R. P., Bowman, L. C., Smith, E. I., & Brodeur, G. M. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.581 · Cited by 594

Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group

London, W. B., Castleberry, R. P., Matthay, K. K., Look, A. T., Seeger, R. C., Shimada, H., Thorner, P., Brodeur, G., Maris, J. M., Reynolds, C. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.571 · Cited by 589

Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma

Attiyeh, E. F., London, W. B., Mossé, Y. P., Wang, Q., Winter, C., Khazi, D., McGrady, P. W., Seeger, R. C., Look, A. T., Shimada, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052399 · Cited by 580

Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma

Otto, T., Horn, S., Brockmann, M., Eilers, U., Schüttrumpf, L., Popov, N., Kenney, A. M., Schulte, J. H., Beijersbergen, R., Christiansen, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.005 · Cited by 573

Randomized phase II clinical trials.

Simon, R. M., Wittes, R. E., & Ellenberg, S. S. (1985) · PubMed · Cited by 482

Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma

Cheung, N.-K. V. (2012) · JAMA · doi:10.1001/jama.2012.228 · Cited by 468

Neuroblastoma Screening at One Year of Age

Schilling, F. H., Spix, C., Berthold, F., Erttmann, R., Fehse, N., Hero, B., Klein, G., Sander, J., Schwarz, K., Treuner, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012277 · Cited by 464

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

Sausen, M., Leary, R. J., Jones, S., Wu, J., Reynolds, C. P., Liu, X., Blackford, A., Parmigiani, G., Diaz, L. A., Papadopoulos, N., et al. (2013) · Nature Genetics · doi:10.1038/ng.2493 · Cited by 414

Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials

Rubinstein, L. V., Korn, E. L., Freidlin, B., Hunsberger, S., Ivy, S. P., & Smith, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.149 · Cited by 408

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

Berthold, F., Boos, J., Burdach, S., Erttmann, R., Henze, G., Hermann, J., Klingebiel, T., Kremens, B., Schilling, F. H., Schrappe, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70291-6 · Cited by 402

High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma

Islam, A., Kageyama, H., Takada, N., Kawamato, T., Takayasu, H., Isogai, E., Ohira, M., Hashizume, K., Kobayashi, H., Kaneko, Y., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203358 · Cited by 386

Copy number variation at 1q21.1 associated with neuroblastoma

Diskin, S. J., Hou, C., Glessner, J. T., Attiyeh, E. F., Laudenslager, M., Bosse, K., Cole, K., Mossé, Y. P., Wood, A., Lynch, J. E., et al. (2009) · Nature · doi:10.1038/nature08035 · Cited by 354

Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma

Janoueix-Lerosey, I., Schleiermacher, G., Michels, E., Mosseri, V., Ribeiro, A., Lequin, D., Vermeulen, J., Couturier, J., Peuchmaur, M., Valent, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0630 · Cited by 349

Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma

Maris, J. M., Mosse, Y. P., Bradfield, J. P., Hou, C., Monni, S., Scott, R. H., Asgharzadeh, S., Attiyeh, E. F., Diskin, S. J., Laudenslager, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708698 · Cited by 319

Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97

Hero, B., Simon, T., Spitz, R., Ernestus, K., Gnekow, A. K., Scheel-Walter, H.-G., Schwabe, D., Schilling, F. H., Benz-Bohm, G., & Berthold, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3349 · Cited by 311

Integrative genomics identifies LMO1 as a neuroblastoma oncogene

Wang, K., Diskin, S. J., Zhang, H., Attiyeh, E. F., Winter, C., Hou, C., Schnepp, R. W., Diamond, M., Bosse, K., Mayes, P. A., et al. (2011) · Nature · doi:10.1038/nature09609 · Cited by 310

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

Capasso, M., Devoto, M., Hou, C., Asgharzadeh, S., Glessner, J. T., Attiyeh, E. F., Mosse, Y. P., Kim, C., Diskin, S. J., Cole, K. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.374 · Cited by 305

Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma

Asgharzadeh, S., Salo, J. A., Ji, L., Oberthuer, A., Fischer, M., Berthold, F., Hadjidaniel, M., Liu, C. W.-Y., Metelitsa, L. S., Pique-Regi, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9169 · Cited by 285

Germline PHOX2B Mutation in Hereditary Neuroblastoma

Mosse, Y. P., Laudenslager, M., Khazi, D., Carlisle, A. J., Winter, C. L., Rappaport, E., & Maris, J. M. (2004) · The American Journal of Human Genetics · doi:10.1086/424530 · Cited by 284

Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma

Diskin, S. J., Capasso, M., Schnepp, R. W., Cole, K. A., Attiyeh, E. F., Hou, C., Diamond, M., Carpenter, E. L., Winter, C., Lee, H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2387 · Cited by 266

Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas

Westermann, F., Muth, D., Benner, A., Bauer, T., Henrich, K.-O., Oberthuer, A., Brors, B., Beissbarth, T., Vandesompele, J., Pattyn, F., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-10-r150 · Cited by 264

ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Hogarty, M. D., Norris, M. D., Davis, K., Liu, X., Evageliou, N. F., Hayes, C. S., Pawel, B., Guo, R., Zhao, H., Sekyere, E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6866 · Cited by 262

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

Yu, A. L., Uttenreuther-Fischer, M. M., Huang, C. S., Tsui, C. C., Gillies, S. D., Reisfeld, R. A., & Kung, F. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2169 · Cited by 250

Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

Shusterman, S., London, W. B., Gillies, S. D., Hank, J. A., Voss, S. D., Seeger, R. C., Reynolds, C. P., Kimball, J., Albertini, M. R., Wagner, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8861 · Cited by 248

Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification

Asgharzadeh, S., Pique-Regi, R., Sposto, R., Wang, H., Yang, Y., Shimada, H., Matthay, K., Buckley, J., Ortega, A., & Seeger, R. C. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj330 · Cited by 237

Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma

Bresler, S. C., Wood, A. C., Haglund, E. A., Courtright, J., Belcastro, L. T., Plegaria, J. S., Cole, K., Toporovskaya, Y., Zhao, H., Carpenter, E. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002950 · Cited by 237

Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641

Strother, D. R., London, W. B., Schmidt, M. L., Brodeur, G. M., Shimada, H., Thorner, P., Collins, M. H., Tagge, E., Adkins, S., Reynolds, C. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9990 · Cited by 234

A population-based study of the usefulness of screening for neuroblastoma

Woods, W. G., Tuchman, M., Robison, L. L., Bernstein, M., Leclerc, J.-M., Brisson, L. C., Brossard, J., Hill, G., Shuster, J., Luepker, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)06020-5 · Cited by 231

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.

Matthay, K. K., DeSantes, K., Hasegawa, B., Huberty, J., Hattner, R. S., Ablin, A., Reynolds, C. P., Seeger, R. C., Weinberg, V. K., & Price, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.229 · Cited by 222

A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

Handgretinger, R., Anderson, K., Lang, P., Dopfer, R., Klingebiel, T., Schrappe, M., Reuland, P., Gillies, S. D., Reisfeld, R. A., & Niethammer, D. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(94)00413-y · Cited by 213

A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants: A Children's Oncology Group Study

Nuchtern, J. G., London, W. B., Barnewolt, C. E., Naranjo, A., McGrady, P. W., Geiger, J. D., Diller, L., Schmidt, M. L., Maris, J. M., Cohn, S. L., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826cbbbd · Cited by 200

Phase I Dose Escalation of Iodine-131–Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study

Matthay, K. K., Tan, J. C., Villablanca, J. G., Yanik, G. A., Veatch, J., Franc, B., Twomey, E., Horn, B., Reynolds, C. P., Groshen, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6400 · Cited by 197

CHD5 , a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas

Fujita, T., Igarashi, J., Okawa, E. R., Gotoh, T., Manne, J., Kolla, V., Kim, J., Zhao, H., Pawel, B. R., London, W. B., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn176 · Cited by 188

Promising Therapeutic Targets in Neuroblastoma

Matthay, K. K., George, R. E., & Yu, A. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1939 · Cited by 187

A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group

Osenga, K. L., Hank, J. A., Albertini, M. R., Gan, J., Sternberg, A. G., Eickhoff, J., Seeger, R. C., Matthay, K. K., Reynolds, C. P., Twist, C., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2000 · Cited by 180

Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo

Johnsen, J. I., Segerström, L., Orrego, A., Elfman, L., Henriksson, M., Kågedal, B., Eksborg, S., Sveinbjörnsson, B., & Kogner, P. (2008) · Oncogene · doi:10.1038/sj.onc.1210938 · Cited by 171

Accumulation of Segmental Alterations Determines Progression in Neuroblastoma

Schleiermacher, G., Janoueix-Lerosey, I., Ribeiro, A., Klijanienko, J., Couturier, J., Pierron, G., Mosseri, V., Valent, A., Auger, N., Plantaz, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7955 · Cited by 168

Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.

Ladenstein, R., Philip, T., Lasset, C., Hartmann, O., Garaventa, A., Pinkerton, R., Michon, J., Pritchard, J., Klingebiel, T., Kremens, B., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.953 · Cited by 165

Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci

Nguyễn, L. B., Diskin, S. J., Capasso, M., Wang, K., Diamond, M. A., Glessner, J., Kim, C., Attiyeh, E. F., Mosse, Y. P., Cole, K., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002026 · Cited by 165

Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study

Bagatell, R., London, W. B., Wagner, L. M., Voss, S. D., Stewart, C. F., Maris, J. M., Kretschmar, C., & Cohn, S. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.7107 · Cited by 160

Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.

Mujoo, K., Kipps, T. J., Yang, H., et al. (1989) · PubMed · Cited by 155

Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study

Park, J. R., Scott, J. R., Stewart, C. F., London, W. B., Naranjo, A. H., Santana, V. M., Shaw, P. J., Cohn, S. L., & Matthay, K. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3293 · Cited by 142

Racial and Ethnic Disparities in Risk and Survival in Children With Neuroblastoma: A Children's Oncology Group Study

Henderson, T. O., Bhatia, R., Pinto, N. R., London, W. B., McGrady, P., Crotty, C., Sun, C., & Cohn, S. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6103 · Cited by 142

Feasibility of Dosimetry-Based High-Dose 131 I-Meta-Iodobenzylguanidine with Topotecan as a Radiosensitizer in Children with Metastatic Neuroblastoma

Gaze, M. N., Chang, Y.-C., Flux, G., Mairs, R. J., Saran, F. H., & Meller, S. T. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.195 · Cited by 141

Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma

Kushner, B. H., Kramer, K., Modak, S. I., & Cheung, N. V. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7272 · Cited by 137

Pilot Study of Iodine-131–Metaiodobenzylguanidine in Combination With Myeloablative Chemotherapy and Autologous Stem-Cell Support for the Treatment of Neuroblastoma

Yanik, G. A., Levine, J. E., Matthay, K. K., Sisson, J. C., Shulkin, B. L., Shapiro, B., Hubers, D., Spalding, S., Braun, T., Ferrara, J. L. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.124 · Cited by 137

Prognostic Impact of Gene Expression–Based Classification for Neuroblastoma

Oberthuer, A., Hero, B., Berthold, F., Juraeva, D., Faldum, A., Kahlert, Y., Asgharzadeh, S., Seeger, R., Scaruffi, P., Tonini, G. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3367 · Cited by 135

Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group

Bernardi, B. D., Mosseri, V., Rubie, H., Castel, V., Foot, A. B. M., Ladenstein, R. L., Laureys, G., Popovic, M. B., Lacerda, A., Pearson, A. D. J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604640 · Cited by 132

A new 123I-MIBG whole body scan scoring method—Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma

Ady, N., Zucker, J. M., Asselain, B. J. R., Edeline, V., Bonnin, F., Michon, J. M., Gongora, R., & Manil, L. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(94)00509-4 · Cited by 130

RETINOID THERAPY OF CHILDHOOD CANCER

Reynolds, C. P., & Lemons, R. S. (2001) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70256-2 · Cited by 129

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

Mossé, Y. P., Lipsitz, E. G., Fox, E., Teachey, D. T., Maris, J. M., Weigel, B. J., Adamson, P. C., Ingle, M. A., Ahern, C. H., & Blaney, S. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3251 · Cited by 120

Differentiating agents in pediatric malignancies: Retinoids in neuroblastoma

Reynolds, C. P. (2000) · Current Oncology Reports · doi:10.1007/s11912-000-0104-y · Cited by 113

Busulfan in hematopoietic stem cell transplant setting

McCune, J. S., & Holmberg, L. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903107764 · Cited by 111

Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification

Liu, X., Mazánek, P., Dam, V., Wang, Q., Zhao, H., Guo, R. J., Jagannathan, J., Cnaan, A., Maris, J. M., & Hogarty, M. D. (2007) · Oncogene · doi:10.1038/sj.onc.1210769 · Cited by 109

Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets

Lawlor, E. R., & Thiele, C. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1921 · Cited by 104

Targeting Ornithine Decarboxylase Impairs Development of MYCN -Amplified Neuroblastoma

Rounbehler, R. J., Li, W., Hall, M. A., Yang, C., Fallahi, M., & Cleveland, J. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2968 · Cited by 103

Detection of MYCN Gene Amplification in Neuroblastoma by Fluorescence In Situ Hybridization: A Pediatric Oncology Group Study

Mathew, P., Valentine, M. B., Bowman, L. C., Rowe, S. T., Nash, M. B., Valentine, V. A., Cohn, S. L., Castleberry, R. P., Brodeur, G. M., & Look, A. T. (2001) · Neoplasia · doi:10.1038/sj.neo.7900146 · Cited by 103

Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature

Preter, K. D., Vermeulen, J., Brors, B., Delattre, O., Eggert, A., Fischer, M., Janoueix‐Lerosey, I., Lavarino, C. E., Maris, J. M., Mora, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2607 · Cited by 100

CAMTA1 , a 1p36 Tumor Suppressor Candidate, Inhibits Growth and Activates Differentiation Programs in Neuroblastoma Cells

Henrich, K., Bauer, T., Schulte, J. H., Ehemann, V., Deubzer, H. E., Gogolin, S., Muth, D., Fischer, M., Benner, A., König, R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3014 · Cited by 100

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)

Schleiermacher, G., Michon, J. M., Ribeiro, A., Pierron, G., Mosseri, V., Rubie, H., Munzer, C., Bénard, J., Auger, N., Combaret, V., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.472 · Cited by 99

Common Variation at BARD1 Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and Oncogenicity

Bosse, K. R., Diskin, S. J., Cole, K. A., Wood, A., Schnepp, R. W., Norris, G. T., Nguyễn, L. B., Jagannathan, J., LaQuaglia, M. P., Winter, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3703 · Cited by 97

Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma

Coughlin, C. M., Fleming, M. D., Carroll, R. G., Pawel, B., Hogarty, M. D., Shan, X., Vance, B. A., Cohen, J. N., Jairaj, S., Lord, E. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3314 · Cited by 96

The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: Results of the German Neuroblastoma Trial NB97

Schmidt, M. C., Simon, T., Hero, B., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.013 · Cited by 95

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

Houghton, P. J., Morton, C. L., Gorlick, R. G., Lock, R. B., Carol, H., Reynolds, C. P., Kang, M. H., Maris, J. M., Keir, S. T., Kolb, E. A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0952 · Cited by 95

Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors

Spunt, S. L., Grupp, S. A., Vik, T. A., Santana, V. M., Greenblatt, D. J., Clancy, J. S., Berkenblit, A., Krygowski, M., Ananthakrishnan, R., Boni, J. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4649 · Cited by 92

Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma

Chanthery, Y. H., Gustafson, W. C., Itsara, M., Persson, A. I., Hackett, C. S., Grimmer, M., Charron, E., Yakovenko, S., Kim, G., Matthay, K. K., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002977 · Cited by 84

Evaluation of semi‐quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma

Messina, J. A., Cheng, S., Franc, B. L., Charron, M., Shulkin, B. L., To, B., Maris, J. M., Yanik, G. A., Hawkins, R. A., & Matthay, K. K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20777 · Cited by 84

Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy

Nath, C. E., Shaw, P. J., Trotman, J., Zeng, L., Duffull, S. B., Hegarty, G., McLachlan, A. J., Gurney, H., Kerridge, I., Kwan, Y. L., et al. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03638.x · Cited by 82

Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

DuBois, S. G., Chesler, L., Groshen, S. G., Hawkins, R. A., Goodarzian, F., Shimada, H., Yanik, G. A., Tagen, M., Stewart, C., Mossé, Y. P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3201 · Cited by 74

Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity

Zwaveling, J., Bredius, R. G. M., Cremers, S. C. L. M., Ball, L. M., Lankester, A. C., Teepe‐Twiss, I. M., Egeler, R. M., den Hartigh, J., & Vossen, J. M. J. J. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704707 · Cited by 71

[131I]meta-Iodobenzylguanidine and Topotecan Combination Treatment of Tumors Expressing the Noradrenaline Transporter

McCluskey, A. G., Boyd, M., Ross, S. C., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0982 · Cited by 65

Replication of Neuroblastoma SNP Association at the BARD1 Locus in African-Americans

Latorre, V., Diskin, S. J., Diamond, M. A., Zhang, H., Hakonarson, H. H., Maris, J. M., & Devoto, M. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0830 · Cited by 61

Fractionated low‐dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high‐risk neuroblastoma

Bradfield, S. M., Douglas, J. G., Hawkins, D. S., Sanders, J. E., & Park, J. R. (2004) · Cancer · doi:10.1002/cncr.20091 · Cited by 54

Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study.

Mossé, Y. P., Balis, F. M., Lim, M. S., Laliberté, J., Voss, S. D., Fox, E., Bagatell, R., Weigel, B. J., Adamson, P. C., Ingle, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.9500 · Cited by 43

CASZ1b, the Short Isoform of CASZ1 Gene, Coexpresses with CASZ1a during Neurogenesis and Suppresses Neuroblastoma Cell Growth

Liu, Z., Naranjo, A. H., & Thiele, C. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018557 · Cited by 39

Global genomic and RNA profiles for novel risk stratification of neuroblastoma

Ohira, M., & Nakagawara, A. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01681.x · Cited by 33

Clinical outcome in children with recurrent neuroblastoma treated with ABT‐751 and effect of ABT‐751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro

Meany, H. J., Sackett, D. L., Maris, J. M., Ward, Y., Krivoshik, A., Cohn, S. L., Steinberg, S. M., Balis, F. M., & Fox, E. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22267 · Cited by 26

Transcriptional adaptation of neuroblastoma cells to hypoxia

Fredlund, E., Ovenberger, M., Borg, Å., & Påhlman, S. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.12.074 · Cited by 25

Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.

Schultz, K. R., Klarnet, J. P., Peace, D. J., et al. (1990) · PubMed · Cited by 23

Screening for neuroblastoma: a resurrected idea?

Maris, J. M., & Woods, W. G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60500-0 · Cited by 21

Elevated Plasma Ferritin and Busulfan Pharmacodynamics During High-dose Chemotherapy Regimens in Children with Malignant Solid Tumors

Bouligand, J., Maître, A. L., Valteau‐Couanet, D., Grill, J., Drouard-Troalen, L., Paci, A., Hartmann, O., Benhamou, E., & Vassal, G. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100168 · Cited by 15

Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy.

Weiser, D. A., Laudenslager, M., Rappaport, E. R., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., London, W. B., Maris, J. M., & Mossé, Y. P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.9514 · Cited by 13

Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group

Irwin, M. S., Naranjo, A., Zhang, F. F., Cohn, S. L., London, W. B., Gastier-Foster, J. M., Ramirez, N. C., Pfau, R., Reshmi, S., Wagner, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00278 · Cited by 494

Neuroblastoma: clinical and biological approach to risk stratification and treatment

Tolbert, V. P., & Matthay, K. K. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2821-2 · Cited by 304

Pharmacologic ascorbate induces neuroblastoma cell death by hydrogen peroxide mediated DNA damage and reduction in cancer cell glycolysis

Ma, E., Chen, P., Wilkins, H. M., Wang, T., Swerdlow, R. H., & Chen, Q. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.09.008 · Cited by 79

YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

Coggins, G. E., Farrel, A., Rathi, K. S., Hayes, C. M., Scolaro, L., Rokita, J. L., & Maris, J. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1415 · Cited by 66